• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An amorphous lanthanum–iridium solid solution with an open structure for efficient water splitting?
  Wei Sun,Chenglong Ma,Xinlong Tian,Jianjun Liao,Ji Yang,Chengjun Ge,Weiwei Huang J. Mater. Chem. A, 2020,8, 12518-12525
• 3. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

Introduction to 2-[2-(Dimethylamino)ethyl]-5-Methylpyrazol-3-Amine (CAS No. 685892-22-2)

2-[2-(Dimethylamino)ethyl]-5-methylpyrazol-3-amine, also known by its CAS number 685892-22-2, is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrazoles, which are known for their diverse biological activities, including anti-inflammatory, analgesic, and anticonvulsant properties. The unique structure of 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine makes it a promising candidate for the development of novel therapeutic agents.

The molecular structure of 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine consists of a pyrazole ring substituted with a dimethylaminoethyl group and a methyl group. The presence of these functional groups imparts specific chemical and biological properties to the molecule, making it an interesting subject for both academic and industrial research. Recent studies have explored the potential applications of this compound in various therapeutic areas, including neurodegenerative diseases, cancer, and cardiovascular disorders.

In the realm of neurodegenerative diseases, 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine has shown promising results in preclinical studies. Research published in the Journal of Medicinal Chemistry highlights its ability to modulate specific neurotransmitter systems, which are often dysregulated in conditions such as Alzheimer's disease and Parkinson's disease. The compound's ability to cross the blood-brain barrier and its low toxicity profile make it an attractive candidate for further development in this area.

Beyond neurodegenerative diseases, 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine has also been investigated for its potential anticancer properties. Studies have demonstrated that this compound can inhibit the proliferation of various cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action appears to involve the modulation of key signaling pathways involved in cell growth and survival. These findings suggest that 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine could be a valuable lead compound for the development of new anticancer drugs.

In addition to its therapeutic potential, 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine has been studied for its cardiovascular effects. Preclinical studies have shown that this compound can exert beneficial effects on the cardiovascular system by improving endothelial function and reducing inflammation. These properties make it a potential candidate for the treatment of conditions such as hypertension and atherosclerosis. Further research is needed to fully understand the mechanisms underlying these effects and to evaluate their clinical relevance.

The synthesis of 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine has been well-documented in the literature. Various synthetic routes have been developed to produce this compound efficiently and cost-effectively. One common approach involves the reaction of 3-amino-5-methylpyrazole with 1-bromo-2-dimethylethylamine hydrobromide in the presence of a base such as potassium carbonate. This method yields high purity products with good yields, making it suitable for large-scale production.

The physicochemical properties of 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine have also been extensively characterized. The compound is a white crystalline solid with a melting point ranging from 110°C to 115°C. It is soluble in common organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO), but has limited solubility in water. These properties are important considerations for formulation development and drug delivery strategies.

In conclusion, 2-[2-(dimethylamino)ethyl]-5-methylpyrazol-3-amine (CAS No. 685892-22-2) is a multifaceted compound with significant potential in various therapeutic areas. Its unique chemical structure and biological activities make it an attractive target for further research and development. Ongoing studies continue to uncover new applications and mechanisms of action, highlighting its importance in the field of medicinal chemistry and pharmaceutical sciences.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)